WALTHAM, Mass. — Arsenal Medical, a clinical-stage company developing medical devices from innovative biomaterials, today announced the complete enrollment of an initial cohort of 10 patients in the EMBO-02 clinical study of NeoCast™ to treat chronic subdural hematomas (cSDH) across three sites in Australia. NeoCast is a next-generation, non-adhesive, solvent-free, liquid embolic material designed for deep distal penetration. EMBO-02 is an open-label, multi-center, prospective clinical trial to evaluate the early safety and feasibility of NeoCast to embolize target vessels of the subject’s middle meningeal artery (MMA) to treat cSDH.
Arsenal Medical Announces Complete Enrollment of the Initial Cohort in the EMBO-02 Study Assessing NeoCast™ for the Treatment of Chronic Subdural Hematoma
